Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular Carcinoma

Although SVR was not independently associated with better survival, patients with SVR had preserved liver function and experienced fewer adverse events. These factors may indirectly support improved tolerability and therapeutic options during Atez/Bev therapy for HCV-related uHCC.

Authors

Institutions

Publication Details

Journal
Oncology
Published
2025-08-08
DOI
https://doi.org/10.1159/000547353
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular Carcinoma

Hideko Ohama, Norio Itokawa, Joji Tani, Hironori Tanaka et al.
2 links
Oncology
Hepatocellular Carcinoma Treatment and Prognosis
article

Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular Carcinoma

Hideko Ohama, Norio Itokawa, Joji Tani, Hironori Tanaka, Kazunari Tanaka, Yuki Kanayama, Tomomitsu Matono, Hidenao Noritake, Kazuhito Kawata, Kazuya Kariyama, Hidenori Toyoda, Hirayuki Enomoto, Kazuhiro Nouso, Hideyuki Tamai, Takeshi Hatanaka, Masatoshi Kudo, Yoichi Hiasa, Teruki Miyake, Kunihiko Tsuji, Atsushi Hiraoka, Takashi Kumada, Shinya Fukunishi, Tomomi Okubo, Takuya Nagano, Ei Itobayashi, Masaki Kaibori, Masashi Hirooka, Hiroki Nishikawa, Hisashi Kosaka, Kazuto Tajiri, Takashi Nishimura, Toshifumi Tada, Atsushi Naganuma, Hironori Ochi, Akemi Tsutsui, Hidekatsu Kuroda, Toru Ishikawa, Yutaka Yata, Masanori Atsukawa, Yuichi Koshiyama, Tomoko Aoki, Fujimasa Tada, Asahiro Morishita, Koichi Takaguchi, Michitaka Imai, Satoru Kakizaki, Kosuke Matsui, Shinichiro Nakamura, Osamu Yoshida, Taeang Arai, Chikara Ogawa
article en

Abstract

Although SVR was not independently associated with better survival, patients with SVR had preserved liver function and experienced fewer adverse events. These factors may indirectly support improved tolerability and therapeutic options during Atez/Bev therapy for HCV-related uHCC.

Oncology
Kansai Medical University (JP), Iwate Medical University (JP), Kagawa University (JP), Hamamatsu University School of Medicine (JP), Wakayama Rosai Hospital (JP), Takamatsu Red Cross Hospital (JP), Saiseikai Niigata Daini Hospital (JP), National Hospital Organization Takasaki Medical Center (JP), Matsuyama Red Cross Hospital (JP), Okayama Prefecture (JP), Ogaki Municipal Hospital (JP), Himeji Medical Center (JP), Hanwa Memorial Hospital (JP), Gunma Saiseikai Maebashi Hospital (JP), Himeji Red Cross Hospital (JP), Teine Keijinkai Hospital (JP), Asahi General Hospital (JP), Toyama University Hospital (JP), Ehime Prefectural Central Hospital (JP), Kagawa Prefectural Central Hospital (JP), Takarazuka City Hospital (JP), Ehime University (JP), Gifu Kyoritsu University (JP), Nippon Medical School (JP), Hyogo University (JP), Osaka University of Pharmaceutical Sciences (JP), Kindai University (JP)
No poverty
Openalex Percentile: Top 71%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.